Zacks: Analysts Anticipate InflaRx N.V. (NASDAQ:LUMO) to Post -$0.67 EPS

Equities research analysts predict that InflaRx N.V. (NASDAQ:LUMO) will post ($0.67) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for InflaRx’s earnings. InflaRx posted earnings per share of ($2.43) in the same quarter last year, which would suggest a positive year-over-year growth rate of 72.4%. The company is expected to report its next earnings report on Tuesday, August 4th.

According to Zacks, analysts expect that InflaRx will report full year earnings of ($2.86) per share for the current fiscal year. For the next financial year, analysts forecast that the business will report earnings of ($3.73) per share. Zacks’ earnings per share calculations are an average based on a survey of analysts that that provide coverage for InflaRx.

InflaRx (NASDAQ:LUMO) last issued its earnings results on Thursday, May 28th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.83) by $0.69. InflaRx had a negative net margin of 3,832.31% and a negative return on equity of 29.17%. The business had revenue of $0.02 million for the quarter.

A number of brokerages have recently weighed in on LUMO. Jefferies Financial Group started coverage on InflaRx in a research report on Thursday, April 16th. They set a “buy” rating and a $12.00 target price on the stock. Roth Capital assumed coverage on shares of InflaRx in a research note on Friday, May 1st. They issued a “buy” rating on the stock. Finally, Zacks Investment Research raised shares of InflaRx from a “hold” rating to a “buy” rating and set a $16.00 target price for the company in a research report on Wednesday, June 17th.

NASDAQ:LUMO traded down $0.46 on Wednesday, hitting $16.53. The stock had a trading volume of 38 shares, compared to its average volume of 35,380. InflaRx has a 52 week low of $6.74 and a 52 week high of $32.40. The company’s fifty day moving average price is $13.55. The company has a market cap of $140.25 million, a P/E ratio of -2.07 and a beta of 1.55.

InflaRx Company Profile

Lumos Pharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for severe, rare, and genetic diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency.

See Also: How Do Investors Open a Backdoor Roth IRA?

Get a free copy of the Zacks research report on InflaRx (LUMO)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for InflaRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InflaRx and related companies with's FREE daily email newsletter.